Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

Core Insights - Gilead Sciences, Inc. reported positive results from the Phase 3 ASCENT-03 study, showing a significant improvement in progression-free survival (PFS) for Trodelvy® compared to chemotherapy in patients with metastatic triple-negative breast cancer (TNBC) [1] Study Findings - The study demonstrated a highly statistically significant and clinically meaningful improvement in PFS for Trodelvy® as a first-line treatment in patients who are not candidates for PD-1/PD-L1 inhibitors [1]